Affymax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AFFY research report →
Price Chart
About the company
Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States.
- CEO
- Jonathan Couchman
- IPO
- 2006
- Employees
- 2
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on AFFY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.99K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.02
- P/B
- -0.02
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
- Gross Margin
- 99.12%
- Op Margin
- -1099.05%
- Net Margin
- -1053.62%
- ROE
- -420.95%
- ROIC
- 916.52%
Latest fiscal year · YoY change
- Revenue
- $1.37M-98.5%
- Gross Profit
- $1.36M-97.3%
- Op Income
- $-15,046,000
- Net Income
- $-14,424,000+84.6%
- EPS
- $-0.39+84.8%
- OCF Growth
- -81.1%
- FCF Growth
- -63.3%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.00
- Beta
- 7.43
- RSI (14)
- 38
- Avg Volume
- 1.86K
No earnings-call transcripts are available for AFFY yet.
- Free Float
- 98.6%
- Shares Outstanding
- 37.49M
- Float Shares
- 36.96M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 28, 13 | WALKER JOHN PETER | sell | 16,040 |
| Aug 28, 13 | WALKER JOHN PETER | sell | 500 |
| Jun 27, 13 | Orwin John A | other | 16,334 |
| Jun 28, 13 | Orwin John A | other | 15,000 |
| Feb 15, 13 | Knapp Jeffrey H | other | 1,015 |
| Feb 15, 13 | Knapp Jeffrey H | other | 313 |
| Feb 15, 13 | Knapp Jeffrey H | other | 1,000 |
| Feb 15, 13 | Knapp Jeffrey H | other | 1,015 |
| Feb 15, 13 | Knapp Jeffrey H | sell | 2,328 |
| Feb 15, 13 | Knapp Jeffrey H | other | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AFFY coverage
Recent articles, reports, and earnings notes.
No research on AFFY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AFFY report →Affymax (OTCMKTS:AFFY) Share Price Passes Above 200 Day Moving Average – Here’s Why
defenseworld.net · Sep 24
Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)
defenseworld.net · Apr 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.